148 related articles for article (PubMed ID: 27078238)
1. [Therapy for irritable bowel syndrome in sight?].
Frieling T
Dtsch Med Wochenschr; 2016 Apr; 141(8):526. PubMed ID: 27078238
[No Abstract] [Full Text] [Related]
2. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
3. ▼ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):90-93. PubMed ID: 28808081
[TBL] [Abstract][Full Text] [Related]
4. [A new remedy for diarrheal irritable bowel syndrome].
Storr M
MMW Fortschr Med; 2016 Mar; 158(5):43. PubMed ID: 26979218
[No Abstract] [Full Text] [Related]
5. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
6. Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.
Keating GM
Drugs; 2017 Jun; 77(9):1009-1016. PubMed ID: 28493170
[TBL] [Abstract][Full Text] [Related]
7. Τ Eluxadoline for IBS-D.
Drug Ther Bull; 2017 Aug; 55(8):91-92. PubMed ID: 28808082
[No Abstract] [Full Text] [Related]
8. Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.
Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
Am J Gastroenterol; 2017 Oct; 112(10):1619-1620. PubMed ID: 28978951
[No Abstract] [Full Text] [Related]
9. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
Özdener AE; Rivkin A
Drug Des Devel Ther; 2017; 11():2827-2840. PubMed ID: 29033544
[TBL] [Abstract][Full Text] [Related]
10. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
11. Eluxadoline: First Global Approval.
Garnock-Jones KP
Drugs; 2015 Jul; 75(11):1305-10. PubMed ID: 26149369
[TBL] [Abstract][Full Text] [Related]
12. Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea.
Shah ED
Dig Dis Sci; 2022 Aug; 67(8):3481-3482. PubMed ID: 35122590
[No Abstract] [Full Text] [Related]
13. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
Vera I; Júdez FJ
Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
[TBL] [Abstract][Full Text] [Related]
14. The latest drug therapies for treating IBS. Longtime sufferers of irritable bowel syndrome have new options for relief.
Health After 50 Sci Am Consum Health; 2015 Dec; 27(12):3. PubMed ID: 27062744
[No Abstract] [Full Text] [Related]
15. Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.
Chey WD; Dove LS; Andrae DA; Covington PS
Aliment Pharmacol Ther; 2017 May; 45(10):1319-1328. PubMed ID: 28326568
[TBL] [Abstract][Full Text] [Related]
16. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
Gawron AJ; Bielefeldt K
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
[TBL] [Abstract][Full Text] [Related]
17. [Prospects for using ladasten preparations in patients with irritable bowel syndrome].
Uspenskiĭ IuP; Fominykh IuA
Eksp Klin Gastroenterol; 2010; (10):75-9. PubMed ID: 21434378
[TBL] [Abstract][Full Text] [Related]
18. In brief: Pancreatitis with eluxadoline (Viberzi) in patients without a gallbladder.
Med Lett Drugs Ther; 2017 Apr; 59(1519):70. PubMed ID: 28419076
[No Abstract] [Full Text] [Related]
19. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
[No Abstract] [Full Text] [Related]
20. IBS: Treating IBS with diarrhoea.
Dickson I
Nat Rev Gastroenterol Hepatol; 2016 Mar; 13(3):124. PubMed ID: 26837711
[No Abstract] [Full Text] [Related]
[Next] [New Search]
